When asked specifically about the role of PSA testing in reducing prostate cancer–specific mortality, PCPs were less likely than urologists to report a belief that PSA can substantially reduce prostate cancer death in screened patients (2 [6.5%] vs 24 [75.0%], respectively). This evidence concerns the gene KLK3 and prostate cancer.